A Two-year, Randomized, Double-masked, Multicentre, Three-Arm Study Comparing the Efficacy and Safety of RTH258 versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration.
Participants are randomised to 3 monthly or 2 monthly treatment.
Trial registry no: NCT02307682
